{
    "hands_on_practices": [
        {
            "introduction": "Administering a gene therapy begins with a fundamental calculation: determining the correct dose for a patient. This exercise will guide you through calculating the total number of vector genomes ($vg$) required based on patient weight, a common practice for adeno-associated virus (AAV) therapies. Furthermore, this practice challenges you to think beyond the simple calculation and consider how unavoidable variability in manufacturing, specifically the product's titer, introduces uncertainty into the actual dose delivered, a critical consideration for ensuring safety and efficacy. ",
            "id": "4951325",
            "problem": "Adeno-associated virus (AAV) gene therapy products are commonly dosed by body mass using vector genomes per kilogram, where the administered quantity is specified in vector genomes (vg). A patient weighing $70$ kilograms requires a weight-based dose targeting $5\\times 10^{13}$ $\\mathrm{vg/kg}$. Using only the definition that a weight-based dose scales proportionally with patient mass and the definition of titer as vector genomes per milliliter, determine the total number of vector genomes to be administered for this patient. Express your final value in vector genomes (vg), in scientific notation, and round your answer to two significant figures.\n\nThen, using the standard definition of coefficient of variation as $CV = \\sigma/\\mu$ and first-order uncertainty propagation, discuss how batch-to-batch variability in the manufacturing titer, characterized by a coefficient of variation $CV_T$, affects uncertainty in the dose actually delivered when the infusion volume is planned using a nominal titer. Your discussion should be based on first principles and should not assume any specialized formulas beyond these definitions. Do not compute any additional numerical quantities beyond the total vector genomes requested; qualitative or symbolic reasoning suffices for the discussion.",
            "solution": "The problem is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. It is based on standard principles of pharmacology, manufacturing science, and statistics. All necessary information is provided. Therefore, a solution will be provided.\n\nThe problem consists of two parts. The first part requires the calculation of the total number of vector genomes to be administered to a patient. The second part requires a discussion of how variability in product titer affects the uncertainty in the delivered dose.\n\nPart 1: Calculation of Total Vector Genomes\n\nThe problem states that the weight-based dose scales proportionally with patient mass. The total quantity of vector genomes to be administered, denoted as $N_{vg}$, is the product of the prescribed dose per unit mass and the total mass of the patient.\n\nLet $m$ be the mass of the patient and $D$ be the weight-based dose. The given values are:\n- Patient mass, $m = 70$ kilograms.\n- Weight-based dose, $D = 5 \\times 10^{13}$ vector genomes per kilogram ($\\mathrm{vg/kg}$).\n\nThe total number of vector genomes is calculated as:\n$$N_{vg} = m \\times D$$\nSubstituting the given values into the equation:\n$$N_{vg} = 70 \\, \\mathrm{kg} \\times (5 \\times 10^{13} \\, \\mathrm{vg/kg})$$\n$$N_{vg} = 350 \\times 10^{13} \\, \\mathrm{vg}$$\nTo express this value in standard scientific notation ($a \\times 10^b$, where $1 \\le |a| < 10$), we rewrite $350$ as $3.5 \\times 10^2$:\n$$N_{vg} = (3.5 \\times 10^2) \\times 10^{13} \\, \\mathrm{vg}$$\n$$N_{vg} = 3.5 \\times 10^{15} \\, \\mathrm{vg}$$\nThe problem requires the answer to be rounded to two significant figures. The calculated value $3.5 \\times 10^{15}$ is already expressed with two significant figures.\n\nPart 2: Discussion of Uncertainty Propagation\n\nThis part requires an analysis of how batch-to-batch variability in the manufacturing titer affects the uncertainty in the dose actually delivered. We are to use first-order uncertainty propagation and the definition of the coefficient of variation ($CV$).\n\nLet's define the relevant quantities:\n- $N_{target}$: The target number of vector genomes to be administered, which we calculated as $3.5 \\times 10^{15} \\, \\mathrm{vg}$. Let's refer to this as $N_{vg}$ for consistency with Part 1.\n- $T_{nom}$: The nominal titer of the AAV product, as stated by the manufacturer (in $\\mathrm{vg/mL}$). This is a fixed value used for planning.\n- $T_{actual}$: The actual titer of the specific batch used for the infusion (in $\\mathrm{vg/mL}$). Due to manufacturing variability, $T_{actual}$ is a random variable.\n- $V_{plan}$: The volume of the product to be infused, calculated based on the nominal titer to achieve the target dose.\n- $N_{actual}$: The actual number of vector genomes delivered to the patient.\n\nThe infusion volume is planned using the target dose and the nominal titer:\n$$V_{plan} = \\frac{N_{vg}}{T_{nom}}$$\nHowever, the actual dose delivered depends on this planned volume and the actual titer of the batch:\n$$N_{actual} = T_{actual} \\times V_{plan}$$\nSubstituting the expression for $V_{plan}$ into the equation for $N_{actual}$:\n$$N_{actual} = T_{actual} \\times \\left(\\frac{N_{vg}}{T_{nom}}\\right) = N_{vg} \\left(\\frac{T_{actual}}{T_{nom}}\\right)$$\nThis equation relates the actual dose delivered to the target dose via the ratio of the actual to nominal titer. The quantities $N_{vg}$ and $T_{nom}$ are constants in this context, while $T_{actual}$ is the source of variability.\n\nWe use first-order uncertainty propagation to determine the variance of $N_{actual}$. For a function $Y = f(X)$, the variance $\\sigma_Y^2$ is approximated by:\n$$\\sigma_Y^2 \\approx \\left(\\frac{df}{dX}\\right)^2 \\sigma_X^2$$\nIn our case, $N_{actual}$ is a function of $T_{actual}$. The derivative is:\n$$\\frac{d N_{actual}}{d T_{actual}} = \\frac{d}{d T_{actual}} \\left[N_{vg} \\left(\\frac{T_{actual}}{T_{nom}}\\right)\\right] = \\frac{N_{vg}}{T_{nom}}$$\nThe variance of the actual dose, $\\sigma_{N_{actual}}^2$, is therefore:\n$$\\sigma_{N_{actual}}^2 \\approx \\left(\\frac{N_{vg}}{T_{nom}}\\right)^2 \\sigma_{T_{actual}}^2$$\nwhere $\\sigma_{T_{actual}}^2$ is the variance of the actual titer across batches.\n\nThe coefficient of variation ($CV$) is defined as the ratio of the standard deviation ($\\sigma$) to the mean ($\\mu$): $CV = \\sigma / \\mu$. The problem provides the coefficient of variation of the titer, $CV_T$. It is reasonable to assume the nominal titer $T_{nom}$ represents the mean of the actual titer distribution, so $\\mu_{T_{actual}} = T_{nom}$.\n$$CV_T = \\frac{\\sigma_{T_{actual}}}{\\mu_{T_{actual}}} = \\frac{\\sigma_{T_{actual}}}{T_{nom}}$$\nWe want to find the coefficient of variation of the delivered dose, $CV_{N_{actual}}$. First, we find the mean of the actual dose delivered, $\\mu_{N_{actual}}$:\n$$\\mu_{N_{actual}} = E[N_{actual}] = E\\left[N_{vg} \\left(\\frac{T_{actual}}{T_{nom}}\\right)\\right] = \\frac{N_{vg}}{T_{nom}} E[T_{actual}] = \\frac{N_{vg}}{T_{nom}} \\mu_{T_{actual}}$$\nUsing our assumption that $\\mu_{T_{actual}} = T_{nom}$:\n$$\\mu_{N_{actual}} = \\frac{N_{vg}}{T_{nom}} T_{nom} = N_{vg}$$\nThis indicates that, on average, the correct dose is delivered.\n\nNow, we can write the expression for $CV_{N_{actual}}$:\n$$CV_{N_{actual}} = \\frac{\\sigma_{N_{actual}}}{\\mu_{N_{actual}}}$$\nThe standard deviation $\\sigma_{N_{actual}}$ is the square root of the variance:\n$$\\sigma_{N_{actual}} \\approx \\sqrt{\\left(\\frac{N_{vg}}{T_{nom}}\\right)^2 \\sigma_{T_{actual}}^2} = \\frac{N_{vg}}{T_{nom}} \\sigma_{T_{actual}}$$\n(We take the positive root as all quantities are positive).\nSubstituting the expressions for $\\sigma_{N_{actual}}$ and $\\mu_{N_{actual}}$:\n$$CV_{N_{actual}} \\approx \\frac{\\frac{N_{vg}}{T_{nom}} \\sigma_{T_{actual}}}{N_{vg}} = \\frac{\\sigma_{T_{actual}}}{T_{nom}}$$\nSince we defined $CV_T = \\sigma_{T_{actual}} / T_{nom}$, we arrive at the conclusion:\n$$CV_{N_{actual}} \\approx CV_T$$\nThis result demonstrates from first principles that the relative uncertainty (as measured by the coefficient of variation) in the manufacturing titer propagates directly to the final dose delivered to the patient. If the titer has a batch-to-batch variability corresponding to a $CV_T$ of, for example, $15\\%$, then the dose received by the patient will also have a relative uncertainty of approximately $15\\%$. This highlights the critical importance of minimizing manufacturing variability to ensure consistent and accurate patient dosing.",
            "answer": "$$\\boxed{3.5 \\times 10^{15}}$$"
        },
        {
            "introduction": "Building on the concept of dose, this next practice delves into the critical issue of potency. For AAV gene therapies, not all viral particles are created equal; some capsids are \"full\" with the therapeutic gene, while others are \"empty\" and inactive. This exercise demonstrates how to quantitatively account for differences in the full-to-empty capsid ratio between manufacturing batches, allowing you to calculate a dose adjustment factor needed to maintain a consistent therapeutic effect. ",
            "id": "4951338",
            "problem": "Adeno-Associated Virus (AAV) gene therapy vectors contain a mixture of capsids that are either full (encapsidating the therapeutic vector genome) or empty (lacking the genome). Only full capsids deliver the transgene to target cells, where the Central Dogma of Molecular Biology (DNA to RNA to Protein) implies that transcription and translation of the delivered gene produce pharmacological effect. Let the fraction of full capsids be denoted by $f$, the administered dose per unit body mass by $D$ in vector genomes per kilogram $\\left(\\mathrm{vg/kg}\\right)$, and the effective vector genomes delivered per kilogram by $L$. Assume a linear exposure-to-effect relationship at the pharmacologically relevant range, so that the effective delivered load is given by the mass balance relation $L = f D$, and the pharmacodynamic effect is proportional to $L$.\n\nFor cross-batch comparison, potency is normalized to a reference full capsid fraction $f_{\\mathrm{ref}}$. Define the potency normalization factor $N$ as the multiplicative factor applied to the observed potency of a batch with full fraction $f$ to yield the potency that would be observed if the batch had full fraction $f_{\\mathrm{ref}}$. A clinical dose $D_{\\mathrm{ref}}$ was previously set using a batch characterized by $f_{\\mathrm{ref}} = 0.70$ to achieve a target delivered load $L_{\\mathrm{target}}$ in $\\mathrm{vg/kg}$. A new clinical batch has $f_{\\mathrm{curr}} = 0.50$.\n\nStarting from the definitions above and the assumption that only full capsids contribute to $L$ and effect, derive symbolic expressions for $N$ and for the dose adjustment factor $A$ required to maintain $L_{\\mathrm{target}}$ when switching from a batch with $f_{\\mathrm{ref}}$ to one with $f_{\\mathrm{curr}}$. Then evaluate both expressions for $f_{\\mathrm{ref}} = 0.70$ and $f_{\\mathrm{curr}} = 0.50$. Express both $N$ and $A$ as dimensionless multiplicative factors. No rounding is required; provide exact values.",
            "solution": "The problem statement has been critically validated and is deemed to be a valid, self-contained, and scientifically grounded problem in pharmacology and bioengineering. All premises are consistent with established principles of gene therapy vectorology and pharmacodynamics. The variables and objectives are clearly defined, and the problem is well-posed, admitting a unique and meaningful solution.\n\nThe problem requires the derivation of two factors: the potency normalization factor, $N$, and the dose adjustment factor, $A$. We will derive each from the given principles.\n\nFirst, we analyze the potency normalization factor, $N$. The problem states that the pharmacodynamic effect, let's denote it by $\\mathcal{E}$, is proportional to the effective delivered load, $L$. This can be written as:\n$$ \\mathcal{E} \\propto L $$\nIntroducing a proportionality constant, $k$, we have:\n$$ \\mathcal{E} = kL $$\nThe effective delivered load $L$ is given by the mass balance relation $L = fD$, where $f$ is the fraction of full capsids and $D$ is the administered dose. Substituting this into the effect equation gives:\n$$ \\mathcal{E} = k f D $$\nPotency, let's call it $P$, is a measure of the effect produced per unit of administered dose. Therefore, we can define it as:\n$$ P = \\frac{\\mathcal{E}}{D} $$\nSubstituting the expression for $\\mathcal{E}$, we find how potency relates to the full capsid fraction:\n$$ P = \\frac{k f D}{D} = kf $$\nThis shows that the observed potency of a batch is directly proportional to its full capsid fraction, $f$.\n\nThe potency normalization factor $N$ is defined as the multiplicative factor applied to the observed potency of a batch with full fraction $f$ to yield the potency that would be observed if the batch had the reference full fraction $f_{\\mathrm{ref}}$. Let $P_{\\mathrm{curr}}$ be the potency of the current batch (with fraction $f_{\\mathrm{curr}}$) and $P_{\\mathrm{ref}}$ be the potency of the reference batch (with fraction $f_{\\mathrm{ref}}$). The definition of $N$ is thus:\n$$ P_{\\mathrm{ref}} = N \\cdot P_{\\mathrm{curr}} $$\nUsing our derived relationship $P=kf$, we can write:\n$$ P_{\\mathrm{curr}} = k f_{\\mathrm{curr}} $$\n$$ P_{\\mathrm{ref}} = k f_{\\mathrm{ref}} $$\nSubstituting these expressions into the definition of $N$:\n$$ k f_{\\mathrm{ref}} = N \\cdot (k f_{\\mathrm{curr}}) $$\nThe constant $k$ is non-zero and cancels, yielding the symbolic expression for $N$:\n$$ N = \\frac{f_{\\mathrm{ref}}}{f_{\\mathrm{curr}}} $$\n\nNext, we derive the dose adjustment factor, $A$. The objective is to maintain a constant target delivered load, $L_{\\mathrm{target}}$, when switching between batches.\nThe target load was established using the reference dose $D_{\\mathrm{ref}}$ and the reference batch characteristics $f_{\\mathrm{ref}}$:\n$$ L_{\\mathrm{target}} = f_{\\mathrm{ref}} D_{\\mathrm{ref}} $$\nWhen using the new batch with full capsid fraction $f_{\\mathrm{curr}}$, a new dose $D_{\\mathrm{curr}}$ is required to achieve the same target load:\n$$ L_{\\mathrm{target}} = f_{\\mathrm{curr}} D_{\\mathrm{curr}} $$\nSince both expressions equal $L_{\\mathrm{target}}$, we can set them equal to each other:\n$$ f_{\\mathrm{ref}} D_{\\mathrm{ref}} = f_{\\mathrm{curr}} D_{\\mathrm{curr}} $$\nThe dose adjustment factor $A$ is defined as the multiplicative factor that relates the new dose to the reference dose, such that $D_{\\mathrm{curr}} = A \\cdot D_{\\mathrm{ref}}$. Substituting this into the equation:\n$$ f_{\\mathrm{ref}} D_{\\mathrm{ref}} = f_{\\mathrm{curr}} (A \\cdot D_{\\mathrm{ref}}) $$\nAssuming the reference dose $D_{\\mathrm{ref}}$ is non-zero, it can be cancelled from both sides:\n$$ f_{\\mathrm{ref}} = f_{\\mathrm{curr}} A $$\nSolving for the symbolic expression for $A$:\n$$ A = \\frac{f_{\\mathrm{ref}}}{f_{\\mathrm{curr}}} $$\nThe symbolic expressions for the potency normalization factor $N$ and the dose adjustment factor $A$ are identical.\n\nFinally, we evaluate these expressions using the given numerical values: $f_{\\mathrm{ref}} = 0.70$ and $f_{\\mathrm{curr}} = 0.50$.\nFor the potency normalization factor $N$:\n$$ N = \\frac{0.70}{0.50} = \\frac{7}{5} = 1.4 $$\nFor the dose adjustment factor $A$:\n$$ A = \\frac{0.70}{0.50} = \\frac{7}{5} = 1.4 $$\nBoth factors are dimensionless. A factor of $1.4$ indicates that the current batch is less potent, and its observed potency must be multiplied by $1.4$ to be comparable to the reference standard. Correspondingly, the administered dose for the current batch must be increased by a factor of $1.4$ to achieve the same therapeutic effect as the reference dose of the reference batch.",
            "answer": "$$ \\boxed{ \\begin{pmatrix} 1.4 & 1.4 \\end{pmatrix} } $$"
        },
        {
            "introduction": "We now shift our focus from dosing to the ultimate pharmacodynamic (PD) outcome. This practice explores the kinetics of how an antisense oligonucleotide (ASO) reduces the concentration of its target protein over time. By modeling protein synthesis and degradation, you will derive the mathematical relationship between the ASO-mediated reduction in messenger RNA ($mRNA$) and the resulting decrease in protein, gaining insight into how a protein's natural turnover rate governs the speed of the therapeutic response. ",
            "id": "4951366",
            "problem": "A pharmacodynamic (PD) analysis of Antisense Oligonucleotide (ASO) action on a target protein is to be built from the Central Dogma of molecular biology and a protein turnover model. Assume the following foundations: messenger ribonucleic acid (mRNA) drives protein synthesis, protein synthesis is proportional to mRNA concentration, and protein degradation follows first-order kinetics. Let $m(t)$ denote the target mRNA concentration and $P(t)$ the target protein concentration. The protein synthesis rate is assumed to be $k_{\\text{syn}} m(t)$, where $k_{\\text{syn}}$ is a constant synthesis proportionality, and protein degradation occurs with a first-order rate constant $k_{\\text{deg}}$ so that the loss rate is $k_{\\text{deg}} P(t)$. Before ASO dosing, the system is at steady state with $m(t)=m_{0}$ and $P(t)=P_{0}$.\n\nAt time $t=0$, a single dose of ASO causes rapid and sustained reduction of the target mRNA to a fixed fraction of baseline, consistent with Ribonuclease H (RNase H) mediated degradation. Specifically, assume $m(t) = (1-\\eta) m_{0}$ for all $t \\ge 0$, where $0 \\le \\eta \\le 1$ is the fractional reduction of mRNA produced by the ASO. The protein concentration is continuous at $t=0$ with $P(0)=P_{0}$.\n\nTasks:\n1. Starting from these assumptions, derive the governing differential equation for $P(t)$ and solve it for $t \\ge 0$ under the described step change in $m(t)$. From your solution, derive the steady-state PD relationship that maps the fractional mRNA reduction $\\eta$ to the fractional protein concentration at long times, expressed as $P_{\\infty}/P_{0}$, where $P_{\\infty}=\\lim_{t \\to \\infty} P(t)$.\n2. Using the derived time course $P(t)$, determine the time $t_{50}$ at which the protein concentration first reaches $0.5 P_{0}$ after ASO administration, expressed in terms of $\\eta$ and $k_{\\text{deg}}$. Then evaluate $t_{50}$ for the specific case $k_{\\text{deg}} = 0.1$ $\\text{h}^{-1}$ and $\\eta = 0.8$.\nExpress the final time in hours and round your numerical answer to four significant figures. Do not use a percentage sign; express all fractional quantities as decimals.",
            "solution": "The user-provided problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n### Step 1: Extract Givens\n-   Target mRNA concentration: $m(t)$\n-   Target protein concentration: $P(t)$\n-   Protein synthesis rate: $k_{\\text{syn}} m(t)$, where $k_{\\text{syn}}$ is a constant.\n-   Protein degradation rate: $k_{\\text{deg}} P(t)$, where $k_{\\text{deg}}$ is a first-order rate constant.\n-   Pre-dosing ($t<0$) steady state: $m(t)=m_{0}$, $P(t)=P_{0}$, and $\\frac{dP}{dt}=0$.\n-   Post-dosing ($t \\ge 0$) mRNA concentration: $m(t) = (1-\\eta) m_{0}$, where $\\eta$ is the fractional mRNA reduction ($0 \\le \\eta \\le 1$).\n-   Initial condition for protein at $t=0$: $P(0)=P_{0}$.\n-   Objective 1: Derive the differential equation for $P(t)$, solve it for $t \\ge 0$, and find the steady-state relationship $P_{\\infty}/P_{0}$, where $P_{\\infty}=\\lim_{t \\to \\infty} P(t)$.\n-   Objective 2: Find the time $t_{50}$ when $P(t_{50}) = 0.5 P_{0}$ in terms of $\\eta$ and $k_{\\text{deg}}$. Evaluate $t_{50}$ for $k_{\\text{deg}} = 0.1$ h$^{-1}$ and $\\eta = 0.8$, rounding to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n-   **Scientifically Grounded**: The problem is based on the Central Dogma of molecular biology and standard pharmacokinetic/pharmacodynamic (PK/PD) modeling principles (first-order kinetics for protein turnover). The mechanism of ASO action via RNase H-mediated mRNA degradation is a well-established concept in pharmacology. The model is a valid and commonly used simplification.\n-   **Well-Posed**: The problem sets up a first-order linear ordinary differential equation with a constant forcing term and a well-defined initial condition. This configuration guarantees a unique and stable solution.\n-   **Objective**: The problem is stated in precise, quantitative terms, free of subjective or ambiguous language.\n-   **Completeness and Consistency**: The problem provides all necessary relationships and conditions. The pre-dosing steady-state condition is key and allows for the determination of relationships between model parameters. The setup is internally consistent.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid as it is scientifically sound, well-posed, and complete. A full solution will be provided.\n\n### Solution Derivation\n\n**Task 1: Governing Equation, Solution, and Steady-State Relationship**\n\nThe rate of change of the protein concentration $P(t)$ is the difference between its synthesis rate and its degradation rate. This gives the governing differential equation:\n$$\n\\frac{dP(t)}{dt} = k_{\\text{syn}} m(t) - k_{\\text{deg}} P(t)\n$$\nBefore ASO administration ($t < 0$), the system is at steady state, meaning $\\frac{dP}{dt} = 0$, with $m(t) = m_0$ and $P(t) = P_0$. Substituting these into the differential equation gives:\n$$\n0 = k_{\\text{syn}} m_0 - k_{\\text{deg}} P_0\n$$\nThis provides a crucial relationship between the parameters at baseline:\n$$\nk_{\\text{syn}} m_0 = k_{\\text{deg}} P_0\n$$\nFor $t \\ge 0$, after the ASO dose, the mRNA level is reduced to $m(t) = (1-\\eta) m_0$. The differential equation for $P(t)$ becomes:\n$$\n\\frac{dP(t)}{dt} = k_{\\text{syn}} (1-\\eta) m_0 - k_{\\text{deg}} P(t)\n$$\nWe can substitute the steady-state relationship $k_{\\text{syn}} m_0 = k_{\\text{deg}} P_0$ into this equation to eliminate the unknown quantities $k_{\\text{syn}}$ and $m_0$:\n$$\n\\frac{dP(t)}{dt} = (1-\\eta) (k_{\\text{deg}} P_0) - k_{\\text{deg}} P(t)\n$$\nThis is a first-order linear ordinary differential equation, which can be rearranged into standard form:\n$$\n\\frac{dP(t)}{dt} + k_{\\text{deg}} P(t) = (1-\\eta) k_{\\text{deg}} P_0\n$$\nThe general solution to an equation of the form $\\frac{dy}{dt} + ay = b$ is $y(t) = \\frac{b}{a} + C \\exp(-at)$, where $C$ is a constant of integration. Here, $y=P(t)$, $a=k_{\\text{deg}}$, and $b=(1-\\eta)k_{\\text{deg}}P_0$. The general solution for $P(t)$ is therefore:\n$$\nP(t) = \\frac{(1-\\eta) k_{\\text{deg}} P_0}{k_{\\text{deg}}} + C \\exp(-k_{\\text{deg}} t)\n$$\n$$\nP(t) = (1-\\eta) P_0 + C \\exp(-k_{\\text{deg}} t)\n$$\nTo find the constant $C$, we apply the initial condition $P(0) = P_0$:\n$$\nP(0) = P_0 = (1-\\eta) P_0 + C \\exp(-k_{\\text{deg}} \\cdot 0)\n$$\n$$\nP_0 = (1-\\eta) P_0 + C\n$$\n$$\nC = P_0 - (1-\\eta) P_0 = P_0 - P_0 + \\eta P_0 = \\eta P_0\n$$\nSubstituting this value of $C$ back into the general solution gives the specific solution for $P(t)$ for $t \\ge 0$:\n$$\nP(t) = (1-\\eta) P_0 + \\eta P_0 \\exp(-k_{\\text{deg}} t)\n$$\nThis can be factored as:\n$$\nP(t) = P_0 \\left[ (1-\\eta) + \\eta \\exp(-k_{\\text{deg}} t) \\right]\n$$\nNext, we derive the steady-state PD relationship. The new steady-state protein concentration, $P_{\\infty}$, is the limit of $P(t)$ as $t \\to \\infty$:\n$$\nP_{\\infty} = \\lim_{t \\to \\infty} P(t) = \\lim_{t \\to \\infty} \\left[ (1-\\eta) P_0 + \\eta P_0 \\exp(-k_{\\text{deg}} t) \\right]\n$$\nSince $k_{\\text{deg}} > 0$, the term $\\exp(-k_{\\text{deg}} t)$ approaches $0$ as $t \\to \\infty$. Thus:\n$$\nP_{\\infty} = (1-\\eta) P_0\n$$\nThe fractional protein concentration at long times is therefore:\n$$\n\\frac{P_{\\infty}}{P_0} = 1-\\eta\n$$\n\n**Task 2: Derivation and Calculation of $t_{50}$**\n\nThe time $t_{50}$ is defined as the time at which the protein concentration reaches $50\\%$ of its baseline value, i.e., $P(t_{50}) = 0.5 P_0$. Note that a solution exists only if the new steady-state level is below $0.5 P_0$, which means $(1-\\eta) < 0.5$, or $\\eta > 0.5$. The provided value $\\eta=0.8$ satisfies this condition.\n\nWe set $P(t_{50}) = 0.5 P_0$ in the solution for $P(t)$:\n$$\n0.5 P_0 = P_0 \\left[ (1-\\eta) + \\eta \\exp(-k_{\\text{deg}} t_{50}) \\right]\n$$\nDividing by $P_0$ (assuming $P_0 \\ne 0$):\n$$\n0.5 = (1-\\eta) + \\eta \\exp(-k_{\\text{deg}} t_{50})\n$$\nNow, we solve for $t_{50}$:\n$$\n0.5 - (1-\\eta) = \\eta \\exp(-k_{\\text{deg}} t_{50})\n$$\n$$\n\\eta - 0.5 = \\eta \\exp(-k_{\\text{deg}} t_{50})\n$$\n$$\n\\frac{\\eta - 0.5}{\\eta} = \\exp(-k_{\\text{deg}} t_{50})\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{\\eta - 0.5}{\\eta}\\right) = -k_{\\text{deg}} t_{50}\n$$\nThe expression for $t_{50}$ in terms of $\\eta$ and $k_{\\text{deg}}$ is:\n$$\nt_{50} = -\\frac{1}{k_{\\text{deg}}} \\ln\\left(\\frac{\\eta - 0.5}{\\eta}\\right) = \\frac{1}{k_{\\text{deg}}} \\ln\\left(\\frac{\\eta}{\\eta - 0.5}\\right)\n$$\nNow, we evaluate $t_{50}$ for the specific case where $k_{\\text{deg}} = 0.1$ h$^{-1}$ and $\\eta = 0.8$:\n$$\nt_{50} = \\frac{1}{0.1} \\ln\\left(\\frac{0.8}{0.8 - 0.5}\\right)\n$$\n$$\nt_{50} = 10 \\ln\\left(\\frac{0.8}{0.3}\\right) = 10 \\ln\\left(\\frac{8}{3}\\right)\n$$\nCalculating the numerical value:\n$$\nt_{50} \\approx 10 \\times 0.98082925...\n$$\n$$\nt_{50} \\approx 9.8082925...\n$$\nRounding the result to four significant figures, we get $9.808$. The unit is hours, as $k_{\\text{deg}}$ is in h$^{-1}$.",
            "answer": "$$\n\\boxed{9.808}\n$$"
        }
    ]
}